Autoimmune hemolytic anemia, also referred to simply as AIHA, is a kind of anemia that is not extremely common. It causes a person's body to form and produce antibodies that turn on its own red blood cells. When this occurs, these cells are eventually permanently destroyed long before they would die a natural death. Liposomal clodronate is a drug that is currently being evaluated by a broad range of researchers in the health the medical field. These individuals are testing the substance to see if it may be a viable treatment for AIHA.
In a vast number of cases, surgery must be performed to treat the aforementioned disorder. As most people are aware of, surgery of any type can result in complications. This is particularly true if the patient is of an advanced age or has additional health issues or underlying diseases.
Individuals who have poor immune systems are usually not appropriate candidates for surgical procedures. In addition, people who take specific drugs may have an increased risk for complications following surgery. This is why most of the clinical studies involving AIHA concentrate on finding new drugs with which to treat the disorder, instead of additional surgical options.
Fortunately, today's modern technology has allowed scientists to isolate the type of agent that is needed to correct the red blood cell destruction that is caused by AIHA: antimacrophage agents are essential in order to stop the destructive activity occurring within the bloodstreams of individuals suffering from AIHA.
According to recent research, liposomally encapsulated clodronate can successfully combat the abnormal production of the antibodies that attack one's red blood cells. Additional trials were conducted to find out if these discoveries were truly as positive as the initial studies indicated.
A two-year study was conducted on mice to test the effectiveness of the drug mentioned above. Two highly different red blood cell antibodies were administered to 2 groups of laboratory mice. The speed at which the destruction of the red blood cells took place dropped significantly when liposomal clodronate was given to both groups of mice.
Health experts and researchers are very optimistic with regard to this substance and its possible advantages for those suffering from AIHA. Numerous scientists believe that using this drug may prove as beneficial as a surgical procedure referred to as a therapeutic splenectomy. Naturally, using liposomally encapsulated clodronate is associated with less risks than any type of surgery. The drug may also be beneficial in instances where a fast response to therapy is crucial.
In addition, positive results were observed when liposomal clodronate was used to suppress macrophage activity in various situations. These included organ transplants, autoimmune diseases, neurological disorders and gene therapy. For this reason, anyone suffering from AIHA has reason to hope that this drug may eventually be developed and marketed as a treatment or even a cure for this destructive blood disorder. However, additional research is still necessary to thoroughly understand all the beneficial effects of the drug.
In a vast number of cases, surgery must be performed to treat the aforementioned disorder. As most people are aware of, surgery of any type can result in complications. This is particularly true if the patient is of an advanced age or has additional health issues or underlying diseases.
Individuals who have poor immune systems are usually not appropriate candidates for surgical procedures. In addition, people who take specific drugs may have an increased risk for complications following surgery. This is why most of the clinical studies involving AIHA concentrate on finding new drugs with which to treat the disorder, instead of additional surgical options.
Fortunately, today's modern technology has allowed scientists to isolate the type of agent that is needed to correct the red blood cell destruction that is caused by AIHA: antimacrophage agents are essential in order to stop the destructive activity occurring within the bloodstreams of individuals suffering from AIHA.
According to recent research, liposomally encapsulated clodronate can successfully combat the abnormal production of the antibodies that attack one's red blood cells. Additional trials were conducted to find out if these discoveries were truly as positive as the initial studies indicated.
A two-year study was conducted on mice to test the effectiveness of the drug mentioned above. Two highly different red blood cell antibodies were administered to 2 groups of laboratory mice. The speed at which the destruction of the red blood cells took place dropped significantly when liposomal clodronate was given to both groups of mice.
Health experts and researchers are very optimistic with regard to this substance and its possible advantages for those suffering from AIHA. Numerous scientists believe that using this drug may prove as beneficial as a surgical procedure referred to as a therapeutic splenectomy. Naturally, using liposomally encapsulated clodronate is associated with less risks than any type of surgery. The drug may also be beneficial in instances where a fast response to therapy is crucial.
In addition, positive results were observed when liposomal clodronate was used to suppress macrophage activity in various situations. These included organ transplants, autoimmune diseases, neurological disorders and gene therapy. For this reason, anyone suffering from AIHA has reason to hope that this drug may eventually be developed and marketed as a treatment or even a cure for this destructive blood disorder. However, additional research is still necessary to thoroughly understand all the beneficial effects of the drug.
About the Author:
Read more about Liposomal Clodronate May Offer Benefits To Those Suffering From Certain Types Of Anemia visiting our website.
No comments:
Post a Comment